Off the wire
Chicago soybeans plunge amid rain forecast for Argentina  • Albania in line with EU policies on Israel-Palestine issue: FM  • Finland gives its first gender equality prize to German Chancellor Merkel  • Malta sees above average proportion of online sales  • U.S. stocks tick down after Fed hikes rates  • 1st LD: Death toll rises to 2 in two stabbing incidents in Dutch city Maastricht  • Xinhua Middle East news summary at 2200 GMT, Dec. 14  • Spotlight: 8th round of intra-Syrian talks in Geneva ends with nothing but division  • Brazil raises growth forecast as economic recovery continues  • Ronaldinho mulls move into politics  
You are here:  

U.S., Mexico vow to tackle cross-border drug trafficking

Xinhua,December 15, 2017 Adjust font size:

WASHINGTON, Dec. 14 (Xinhua) -- The U.S. and Mexican high-level officials met here on Thursday to discuss strategies to clamp down transnational criminal organizations (TCO) and illegal drug flow with joint efforts.

Calling the TCOs and the drugs "grave" problems, U.S. Deputy Secretary of State John Sullivan told a press conference that only close collaboration can tackle the threats.

In 2016, more than 64,000 Americans died from drug overdose, with death toll from synthetic opioids alone claiming more lives than both heroin and prescription painkillers, according to preliminary figures from the U.S. government.

Meanwhile, many Mexicans have fallen victim to drug-related violence.

U.S. Secretary of Homeland Security Kirstjen Nielsen told reporters that to strengthen the bilateral cooperation, a memorandum will be signed on Thursday through which U.S. criminal history of repatriated Mexicans could be shared with Mexico.

Cross-border crime and drug trafficking have long been a threat to the two neighboring countries, which traditionally blamed each other for drug demand and supply.

Urging the two sides to overcome the "blame game," Mexican Foreign Secretary Luis Videgaray Caso called for "trust" and "effective actions."

Sullivan also noted the necessity for the United States to reduce their drug demand at home.

"As long as we continue to provide a thriving market, TCOs will keep coming to the United States," he said. Enditem